Cohere Health vs Moderna
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $50M equity ($106M total). Processes 5.5M prior authorizations/year for 15M health plan members and 420,000 providers. CMS 2026 deadline a direct growth catalyst.
About
Cohere Health (not affiliated with the AI company Cohere) is a prior authorization intelligence platform operating on the payer side of healthcare — a differentiated position from provider-facing prior auth tools. The company has raised $106 million in total equity financing and processes 5.5 million prior authorizations annually covering 15 million health plan members and 420,000 provider relationships for its health plan customers.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
About
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.